Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy

Trial Profile

Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs VAY 736 (Primary) ; Ibrutinib
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 26 Jul 2020 to 5 Sep 2019.
    • 23 Jan 2018 Planned primary completion date changed from 26 Jul 2019 to 5 Sep 2019.
    • 23 Jan 2018 Planned initiation date changed from 15 Jan 2018 to 23 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top